When SARS-CoV-2 binds to ACE2 receptor, it decreases ACE2 levels, thus disrupting the ACE1/ACE2 balance and causing RAAS activation, which may aggravate COVID-19 symptoms in the lungs, especially in patients with comorbidities [64,65]. Here, ACE2 is linked to COVID-19.